
Neumora Therapeutics Investor Relations Material
Latest events

Q1 2025
Neumora Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Neumora Therapeutics Inc
Access all reports
Neumora Therapeutics Inc., known as NMRA, is a clinical-stage biopharmaceutical company focused on the development of therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. Founded in 2019 and formerly known as RBNC Therapeutics, Inc., Neumora aims to redefine neuroscience drug development by integrating data science with neuroscience to pioneer precision medicines for complex brain diseases. The company's pipeline includes various programs at different stages of clinical trials targeting diseases such as major depressive disorder, agitation associated with dementia due to Alzheimer's disease, schizophrenia, amyotrophic lateral sclerosis, and Parkinson's disease, among others. The company is headquartered in Watertown, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
Ticker symbol
NMRA
Country
🇺🇸 United States